Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Non-Current Liabilities (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $396.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 13.12% year-over-year to $396.0 million, compared with a TTM value of $396.0 million through Sep 2025, up 13.12%, and an annual FY2024 reading of $355.0 million, up 34.69% over the prior year.
  • Total Non-Current Liabilities was $396.0 million for Q3 2025 at Autolus Therapeutics, up from $374.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $396.0 million in Q3 2025 and bottomed at -$214.6 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $240.5 million, with a median of $291.3 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities rose 9.39% in 2021, then skyrocketed 203.21% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $92.1 million in 2021, then skyrocketed by 107.88% to $191.5 million in 2022, then skyrocketed by 37.64% to $263.6 million in 2023, then skyrocketed by 34.69% to $355.0 million in 2024, then increased by 11.56% to $396.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for AUTL at $396.0 million in Q3 2025, $374.0 million in Q2 2025, and $374.8 million in Q1 2025.